AXON, market cap 1.26 Billion. What is their great
Post# of 72447
(Total Views: 335)
Posted On: 01/12/2017 10:01:44 PM
AXON, market cap 1.26 Billion. What is their great platform? Why, they are going to try to revive an Alzheimer's drug that was abandoned by Big Pharma because it, well, didn't work. Just like the many similar drugs that work the same way, which Big Pharma has abandoned because they, well, didn't work.
Here's their chart.
http://bigcharts.marketwatch.com/advchart/fra...mp;state=9
Looks great, huh? Cut in half from the IPO price. Wall Street big money insiders put this POS on the market, and you can see when the end of the lock-up period was, because they ran it back up on fake news, sold their positions, and now it's languishing here. Eventually it will croak.
So tell me -- is this stock worth 9 or 10 times CTIX's market cap? Let's see, what do I want to buy --
AXON -- failed Alzheimer's drug. Alzheimer's clinical trials take a very long time because of the slowly progressive nature of the disease.
-OR -
CTIX. 3 drugs in 5 clinical trials. All clinical trials thus far have been successful. News expected within months.
Gee, I wonder. Should I pay a lot for a company with a product that has already failed once, or should I pay a little for a company with not 1 but 5 clinical trials for different applications. I wonder -- but the time of my wondering is measured in nanoseconds.
Here's their chart.
http://bigcharts.marketwatch.com/advchart/fra...mp;state=9
Looks great, huh? Cut in half from the IPO price. Wall Street big money insiders put this POS on the market, and you can see when the end of the lock-up period was, because they ran it back up on fake news, sold their positions, and now it's languishing here. Eventually it will croak.
So tell me -- is this stock worth 9 or 10 times CTIX's market cap? Let's see, what do I want to buy --
AXON -- failed Alzheimer's drug. Alzheimer's clinical trials take a very long time because of the slowly progressive nature of the disease.
-OR -
CTIX. 3 drugs in 5 clinical trials. All clinical trials thus far have been successful. News expected within months.
Gee, I wonder. Should I pay a lot for a company with a product that has already failed once, or should I pay a little for a company with not 1 but 5 clinical trials for different applications. I wonder -- but the time of my wondering is measured in nanoseconds.
(0)
(0)